A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.
Kiyotani K, Uno S, Mushiroda T, Takahashi A, Kubo M, Mitsuhata N, Ina S, Kihara C, Kimura Y, Yamaue H, Hirata K, Nakamura Y, Zembutsu H. A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr; 22(4):229-35.